- call +1-201-465-4211
- email sales@mrinsights.biz
This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising pipeline drugs and novel therapies, rising investments in innovation of inhibitor drugs and increasing HAE awareness programs are the major drivers of the global plasma protease C1-inhibitors treatment market.
Scope of the Report:
Based on drug class, the market has been segmented into C1-inhibitors (C1-esterase Inhibitor, Recombinant Inhibitor); Kallikrein Inhibitor (Kalbitor); Selective Bradykinin B2 Receptor Antagonist (Firazyr). The drug class market segments have been analyzed based on available approved products, cost-effectiveness, and preference given by the physicians for the treatment of HAE patients.
The global Plasma Protease C1-inhibitor Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Plasma Protease C1-inhibitor Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Plasma Protease C1-inhibitor Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Plasma Protease C1-inhibitor Treatment market by product type and applications/end industries.
Market Segment by Companies, this report covers
Shire plc
CSL Limited
Sanquin
Pharming Group N.V.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
C1-inhibitors
Kallikrein Inhibitor (Kalbitor)
Market Segment by Applications, can be divided into
Hospital Pharmacies
Independent Pharmacies and Outlets
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Plasma Protease C1-inhibitor Treatment Market Overview
1.1 Product Overview and Scope of Plasma Protease C1-inhibitor Treatment
1.2 Classification of Plasma Protease C1-inhibitor Treatment by Types
1.2.1 Global Plasma Protease C1-inhibitor Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Plasma Protease C1-inhibitor Treatment Revenue Market Share by Types in 2017
1.2.3 C1-inhibitors
1.2.4 Kallikrein Inhibitor (Kalbitor)
1.3 Global Plasma Protease C1-inhibitor Treatment Market by Application
1.3.1 Global Plasma Protease C1-inhibitor Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Pharmacies
1.3.3 Independent Pharmacies and Outlets
1.4 Global Plasma Protease C1-inhibitor Treatment Market by Regions
1.4.1 Global Plasma Protease C1-inhibitor Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Plasma Protease C1-inhibitor Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Plasma Protease C1-inhibitor Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Plasma Protease C1-inhibitor Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Plasma Protease C1-inhibitor Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Plasma Protease C1-inhibitor Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Plasma Protease C1-inhibitor Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Shire plc
2.1.1 Business Overview
2.1.2 Plasma Protease C1-inhibitor Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Shire plc Plasma Protease C1-inhibitor Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 CSL Limited
2.2.1 Business Overview
2.2.2 Plasma Protease C1-inhibitor Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 CSL Limited Plasma Protease C1-inhibitor Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 Sanquin
2.3.1 Business Overview
2.3.2 Plasma Protease C1-inhibitor Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Sanquin Plasma Protease C1-inhibitor Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pharming Group N.V.
2.4.1 Business Overview
2.4.2 Plasma Protease C1-inhibitor Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Pharming Group N.V. Plasma Protease C1-inhibitor Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Plasma Protease C1-inhibitor Treatment Market Competition, by Players
3.1 Global Plasma Protease C1-inhibitor Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Plasma Protease C1-inhibitor Treatment Players Market Share
3.2.2 Top 10 Plasma Protease C1-inhibitor Treatment Players Market Share
3.3 Market Competition Trend
4 Global Plasma Protease C1-inhibitor Treatment Market Size by Regions
4.1 Global Plasma Protease C1-inhibitor Treatment Revenue and Market Share by Regions
4.2 North America Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
5 North America Plasma Protease C1-inhibitor Treatment Revenue by Countries
5.1 North America Plasma Protease C1-inhibitor Treatment Revenue by Countries (2013-2018)
5.2 USA Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
6 Europe Plasma Protease C1-inhibitor Treatment Revenue by Countries
6.1 Europe Plasma Protease C1-inhibitor Treatment Revenue by Countries (2013-2018)
6.2 Germany Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
6.4 France Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue by Countries
7.1 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue by Countries (2013-2018)
7.2 China Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
7.5 India Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
8 South America Plasma Protease C1-inhibitor Treatment Revenue by Countries
8.1 South America Plasma Protease C1-inhibitor Treatment Revenue by Countries (2013-2018)
8.2 Brazil Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Plasma Protease C1-inhibitor Treatment by Countries
9.1 Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Plasma Protease C1-inhibitor Treatment Revenue and Growth Rate (2013-2018)
10 Global Plasma Protease C1-inhibitor Treatment Market Segment by Type
10.1 Global Plasma Protease C1-inhibitor Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Plasma Protease C1-inhibitor Treatment Market Forecast by Type (2018-2023)
10.3 C1-inhibitors Revenue Growth Rate (2013-2023)
10.4 Kallikrein Inhibitor (Kalbitor) Revenue Growth Rate (2013-2023)
11 Global Plasma Protease C1-inhibitor Treatment Market Segment by Application
11.1 Global Plasma Protease C1-inhibitor Treatment Revenue Market Share by Application (2013-2018)
11.2 Plasma Protease C1-inhibitor Treatment Market Forecast by Application (2018-2023)
11.3 Hospital Pharmacies Revenue Growth (2013-2018)
11.4 Independent Pharmacies and Outlets Revenue Growth (2013-2018)
12 Global Plasma Protease C1-inhibitor Treatment Market Size Forecast (2018-2023)
12.1 Global Plasma Protease C1-inhibitor Treatment Market Size Forecast (2018-2023)
12.2 Global Plasma Protease C1-inhibitor Treatment Market Forecast by Regions (2018-2023)
12.3 North America Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2018-2023)
12.6 South America Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Plasma Protease C1-inhibitor Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Plasma Protease C1-inhibitor Treatment Picture
Table Product Specifications of Plasma Protease C1-inhibitor Treatment
Table Global Plasma Protease C1-inhibitor Treat
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
